Innohep, also known as Tinzaparin Sodium, is used together with another drug, Warfarin, to treat blood clots that have occurred deep in the veins of hospitalized patients who may or may not have also experienced the occurrence of blood clots in their lungs (pulmonary embolism). Innohep is used for several days after surgery, when patients are unable to walk. It is during this time that blood clots are most likely to form. The drug works by inhibiting Factor Xa, a key component involved in blood clotting. Innohep, approved by the U.S. Food and Drug Administration in 2000, is made by DuPont Pharmaceuticals.

The major side effect of Innohep is excessive bleeding. Innohep is not to be used in patients with severely impaired kidney function or in patients who weigh less than 110 pounds, because they may have an increased risk for serious bleeding. Elderly patients also may be more likely to experience serious bleeding complications.

In addition, the labeling for Innohep includes a black box warning. The boxed warning cautions physicians that patients on Innohep who undergo spinal anesthesia or spinal puncture are at risk of developing a blood clot in the spine. Patients who develop a blood clot in the spine may be paralyzed permanently.

See your doctor if you have experienced an adverse reaction after being administered Innohep. In addition, it may be important to contact an attorney who can help you protect your legal rights. Please keep in mind that there may be time limits within which you must commence suit.

See Also

  1. Blood Thinning Drugs: Overview
  2. Blood Clots
  3. Excessive Bleeding: Overview
  Name Size
- Winter Leaves.jpg 206.26 KB